Post on 22-Feb-2016
description
1
ICON Plc.Raymond James – 30th Annual Institutional Investors
March 11th 2009
2
Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Forward Looking Statements
3
Global Full Service Clinical Development
US 45%
EU 47%
ROW 8%
4
ICON’s Global Footprint
5
ICON plc Staff Growth 1990 - Today
5 18 40 70 100 180 250 340 580830
1300 15001995
2418 25883036
4293
5292
6975
6
Market Environment
7
Market Fundamentals still intact
• Continued R&D Spending Growth.¯ Pipelines continue to strengthen¯ Scientific innovation continues to expand
• Increased Outsourcing ¯ Globalisation of clinical research¯ New strategic thinking / cost containment
• Increasing Regulation ¯ More patients/ more studies¯ Post marketing surveillance
8
Continued R&D Spending Growth
9
Continued R&D Spending Growth
10
Phase I Pipeline Robust
Source Goldman Sachs
11
Positive trends in Phase II / III
Source Goldman Sachs
12
Compounds in development growing across all therapeutic areas
Source Goldman Sachs
13
Market Fundamentals still intact
• Continued R&D Spending Growth.¯ Pipelines continue to strengthen¯ Scientific innovation continues to expand
• Increased Outsourcing ¯ Globalisation of clinical research¯ New strategic thinking / cost containment
• Increasing Regulation ¯ More patients/ more studies¯ Post marketing surveillance
14
• Clients are increasingly focused on their core competencies of¯ Discovery¯ Strategic Development¯ Marketing
• Clients are asking CROs to take more responsibility
• Scientific/medical depth will be increasingly important
• Clients likely to move their % outsourced from ≈ 30% to >50% over the next 5+ years
Increased Outsourcing
15
Market Fundamentals still intact
• Continued R&D Spending Growth.¯ Pipelines continue to strengthen¯ Scientific innovation continues to expand
• Increased Outsourcing ¯ Globalisation of clinical research¯ New strategic thinking / cost containment
• Increasing Regulation ¯ More patients/ more studies¯ Post marketing surveillance
16
Opportunities…. but also Risks
17
ICON in this Market Environment
18
Value of RFPsGross, Net and by Origination Region
18
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
$8,000
2003 2004 2005 2006 2007 2008
(in m
illion
s)
Gross Net US (Net) EU (Net) ROW (Net)
(Gross includes RFPs that never progressed to award)
1919
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
$8,000
2003 2004 2005 2006 2007 2008
(in m
illion
s)
Gross Net US (Net) EU (Net) ROW (Net)
Value of RFPsGross, Net and by Execution Region
(Gloss includes RFPs that never progressed to award)
20
Net New Business wins and book to bill ratios
$230 $230
$344$369
$337$350
$261
Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08
1.6
1.8
1.6
1.2
1.51.9
1.4
Net Business Wins Book to Bill Ratio
21
50% Large Pharma18% Mid Pharma
7% Non-Rev Co’s
Analysis of 2008 Business Wins
13% Large Bio
12% Mid Bio
22
Total Backlog levels. ($ millions)
$1,049$1,125
$1,300
$1,486
$1,633
$1,736 $1,748
Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08
23
Coverage of next 4 quarters from backlog
$493$542
$589
$690
$752 $762$707
Q2 07 Q3 '07 Q4 '07 Q1 08 Q2 08 Q3 08 Q4 08
77%77% 76% 77%
74%
76% 77%
Value of backlog forecast to be earned in next 4 quarters
% coverage of next 4 quarters forecast revenues
24
Projects of longer duration leads to slower backlog burn
15.3%15.9% 16.0% 15.5%
14.6%13.8%
12.7%
Q2 07 Q3 '07 Q4 '07 Q1 08 Q2 08 Q3 08 Q4 08
25
Quality
26
Quality and Delivery remain our Key Focus.
27
2007 2008
ICON Internal Audits 863 870
Client & ISO Audits 255 219
Total 1118 1089
We are extensively audited (internally and by clients)
28
Office Date Region Auditing Authority Outcome
Redwood City, CA Oct 2003 US FDA No findings (no FDA 483)
New York City, NY Mar/Apr 2005 US FDA No findings (no FDA 483)
North Wales, PA May 2005 US FDA No findings (no FDA 483)
Nashville, TN Oct/Nov 2005 US FDA No findings (no FDA 483)
North Wales, PA Dec 2005 US FDA No findings (no FDA 483)
Nashville, TN Jan 2006 US FDA No findings (no FDA 483)
Eastleigh, UK Oct 2004 EU MHRA No critical findings
Dublin, Ireland Apr 2005 EU IMB No critical findings
Eastleign/Marlow, UK Sept 2007 EU MHRA No critical findings
Frankfurt. Germany Sept 2007 EU Local regulatory authority: RP Darmstadt No critical findings
Singapore Oct 2005 ROW HSA - Health Services Authority of Singapore No critical findings
Excellent record of regulatory agency inspections
29
Strategy
30
ICON’s Core Strategy is Organic Growth,with acquisitions made to add new services or scale.
Capitalise on market fundamentals to drive organic growth in all business units.
Cross-sell services to grow sales and margin
Pursue acquisitions to enhance depth and scale of current operations and to add additional complementary services e.g.
Phase I
Bioanalytical / Biomarkers
Therapeutic specialists
Safety / Late Phase
Japan
Acquisitions to date - 12
• Revenues acquired $130m
• Staff acquired – 1,200
• => Organic growth >80%
31
Financial Performance
32
Net Revenue CAGR of over 30% since 2005
$865
$631
$456
$327
$955
$0
$100
$200
$300
$400
$500
$600
$700
$800
$900
$1,000
FY2005 FY2006 FY2007 FY2008 FY2009*
Mill
ions
CAGR 31%
* Mid Point of 2009 Guidance
(E)
33
Earnings Per Share Growth
$0.43
$0.68
$0.94
$1.30
$1.46
$0.00
$0.20
$0.40
$0.60
$0.80
$1.00
$1.20
$1.40
$1.60
FY2005 FY2006 FY2007 FY2008 FY2009*
CAGR 36%
(E)
* Mid Point of 2009 Guidance
34
Recent Financial Performance ($ millions)
31 Dec FY 2008
31 Dec FY 2007
% Increase
Net Revenue 865 631 37%
Direct Costs 489 354 38%
SG & A 248 189 32%
D & A 28 19 46%_____ _____ _____
Operating Income 100 69 44%Operating Margin 11.5% 11%
Net Income 78 56 40%_____ _____ _____
EPS (Inc SFAS 123R) 130c 94c 38%
Weighted Average no. of Shares (Inc SFAS123R)
60.2m 59.5m 1.2%
35
Recent Financial Performance ($ millions)
Q4 2008 Q4 2007 % Increase
Net Revenue 220 181 22%
Direct Costs 125 100 25%
SG & A 62 56 11%
D & A 7 5 31%_____ _____ _____
Operating Income 26 20 34%Operating Margin 12% 11%
Net Income 21 16 32%_____ _____ _____
EPS (Inc SFAS 123R) 35c 26c 35%
Weighted Average no. of Shares (Inc SFAS123R)
59.9m 60m
36
Summary Balance Sheet and Cash Flow ($ millions)
Dec 31, 08 Dec 31, 07 (Year)
Net (Debt)/Cash ($4.3) $23.8
Total assets $867.3 $693.1
Shareholder’s equity $456.4 $388.4
Cashflow from operations $81.3 $42.9
Capital expenditures $67.9 $75.4
CAPEX Excl. Dublin Extn. $46.0 $36.8
37
• Top Global Clinical CRO - #4• Excellent strategic position• Solid market fundamentals • Outstanding record of growth • Strong balance sheet
Investment Case Summary